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ABSTRACT
Methods: A cost-effectiveness model was designed comparing empiric treatment of VAP with DOR versus IMI from the health insurance perspectives. 
The differences in the total costs and quality-adjusted life years (QALYs) under each scenario were examined, and sensitivity analyses were conducted 
to determine the stability of our estimates. Drug costs were taken from health insurance hospitals, with other inputs derived from the literature.
Results: Deterministic baseline results from the model of DOR compared to IMI in the treatment of VAP suggest that DOR is more effective and less 
expensive than IMI. The total costs for IMI and DOR were Egyptian pound (EGP) 4646.93 and EGP 4197.58, respectively. QALYs for IMI and DOR were 
0.53 and 0.54, respectively.
Conclusions: Given the microbiologic sensitivity profile of PA to DOR and IMI, and depending on the local susceptibility patterns in institutions where 
DOR in vitro susceptibilities are superior to those of other carbapenems for PA clinical isolates, empiric treatment of VAP with DOR may dominate that 
with IMI by being both life- and cost-saving.
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INTRODUCTION
Ventilator-associated pneumonia (VAP) means nosocomial pneumonia 
occurring 48 hrs or more after initiation of mechanical ventilation 
(MV) [1]. VAP is the most common Hospital-Associated Infection among 
adult patients in intensive care units (ICUs), with frequencies ranging 
from 15% to 45% [2]. Increase in hospital morbidity, mortality, duration 
of hospitalization by an average of 7-9 days per patient, and increase in 
health-care costs were associated with VAP [3,4]. The incidence rates 
of VAP are higher in developing countries with limited resources [5].
The pathogenesis of VAP involves bacterial invasion of the pulmonary 
parenchyma in patients receiving MV. Inoculation of the previously 
sterile lower respiratory tract results from aspiration of secretions, 
colonization of the aerodigestive tract, or use of contaminated 
equipment or medications [6].
VAP is caused by such resistant organisms as methicillin-resistant 
Staphylococcus aureus and Pseudomonas aeruginosa (PA) [7]. Hence, 
because inappropriate empiric therapy for VAP leads to a higher hospital 
mortality rate [8,9], broad coverage for such pathogens, followed by de-
escalation, is an evidence-based recommendation.
Imipenem/cilastatin (IMI) is a broad spectrum antibiotic possessing 
activity against clinically important aerobic Gram-positive, Gram-
negative species, and anaerobes [10]. IMI is commonly used and 
recommended first-line therapies for hospital acquired pneumonia 
and VAP in patients at high risk for resistant pathogens. Recently, PA 
resistance to IMI has become an increasing challenge in VAP treatment. 
Doripenem (DOR) is a novel, broad-spectrum parenteral carbapenem 
antimicrobial. It shows an enhanced in vitro potency against PA and a 
more favorable sensitivity pattern among PA isolates [11]. Because of 
these more favorable susceptibility patterns, empiric DOR use when IMI 
resistance is likely may improve both clinical and resource utilization 
outcomes.
The objective of this study was to evaluate the cost-effectiveness of IMI 
versus DOR in VAP from the health insurance perspective over a time 
horizon of 15 days.
METHODS
It is important to identify the most cost-effective treatment in patients 
with VAP. Decision analysis is a quantitative method for synthesizing 
data from numerous sources for the evaluation of treatment alternatives 
and was developed to determine the cost-effectiveness of the IMI 
strategy, as compared to DOR in patients with VAP.
The literature search was conducted in Medline, PubMed, and Cochrane 
Library to identify relevant published English articles from January 
2000 to October 2016. The decision analytical model was constructed 
to assess the costs and consequences associated with IMI compared 
with DOR. The clinical parameters were derived mainly from two 
sources; the first was a prospective, multicenter, parallel randomized, 
active-controlled, open-label study that compares DOR versus IMI on 
531 patients with VAP. The model structure was derived from the cost-
effectiveness model of empiric DOR compared with IMI in VAP in the 
United States [12,13].
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Objective:  One  of  the  most  common  complications  of  critical  illness  among  surgical  and  trauma  patients  is  ventilator-associated 
pneumonia (VAP). The mortality rate increases due to inappropriate empiric treatment of VAP. The rates of Pseudomonas aeruginosa (PA) 
VAP  susceptibility  to  doripenem  (DOR)  are  higher  than  those  to  imipenem-cilastatin  (IMI).  Cost-effectiveness  analysis  was  developed  to 
define outcome differences between strategies of empiric treatment of VAP with DOR versus IMI in Egyptian patients.
The utilities were derived from two sources; the first was a cost-utility 
analysis that used Markov model to compare meropenem with IMI in 
the treatment of severe infections in intensive care. The study elicits the 
utility scores from the EuroQoL (EQ-5D) social tariff for “unconscious” 
patients in the United Kingdom [14]. The second source was a cost-
effectiveness model of empiric DOR compared with IMI in VAP that used 
utilities estimated using time-trade off questions from 1005 patients 
enrolled in a five-center study of seriously ill patients [13].
This is an analysis of publicly accessible data; no human subjects were 
enrolled in the study. All calculations were performed in Excel 2016. The 
target population is Egyptian patients in the health-care system, no subgroup 
analysis. Total costs include costs of treatment and managing strategies 
according to the Egyptian current practice. The source of costs was the 
hospitals. The outcomes of the two treatments were measured in terms of 
quality-adjusted life-years (QALYs). The method used; EQ5D from published 
literature. All lives, life years, or QALYs are valued equally, regardless of age, 
gender, or socioeconomic status of individuals in the population. Critical 
component (s) in the calculation is varied through a relevant range or from 
worst case to best case. One-way sensitivity analysis is performed.
Model overview and structure
A cost-effectiveness model was developed of DOR versus IMI as the 
initial empiric antibiotic for VAP in patients on MV. In a decision analysis 
approach, a single decision node represented the choice to treat VAP 
with DOR or IMI in patients on MV. This cohort was marched through 
each branch of the decision tree to either death or VAP resolution and 
calculated the incremental costs associated with each choice (Fig. 1).
The parameters for the incidence of PA-VAP and its clinical and 
economic consequences were derived from a review of literature and 
other publicly accessible data (Table 1). We defined cost-effectiveness 
from the health insurance perspective as the ratio between total 
hospital cost differences and the differences in QALY between the two 
strategies.
Because of the uncertainty surrounding various model parameters, 
sensitivity analyses was performed to assess the precision and stability 
of the observations. The 95% confidence intervals (CIs) around the 
point estimates were calculated.
Patterns of DOR and IMI susceptibility among PA
In a microbiology registry of 270PA isolates from patients in the ICU, 
220 (81.5%) were DOR sensitive (DOR-S); of those, 21 (7.8%) were 
also IMI resistant (IMI-R) and 50 (18.5%) were DOR-R, with the rate 
of IMI-S in this group of 1 (0.4%) [12]. Drug sensitivity was defined on 
the basis of the current U.S. Food and Drug Administration thresholds 
for each drug: For IMI, a minimum inhibitory concentration (MIC) 
Table 1: Model inputs 
Parameters Base case Low value High value References
IMI 500 mg/6 hrs
Probability of being IMI-S 0.741 0.685 0.789 Zilberberg et al., 2010
Probability of being IMI-R/DOR-S 0.078 0.052 0.116 Zilberberg et al., 2010
Probability of being resistant to both treatments (IMI-R/
DOR-R)
0.181 0.1448 0.2172 Zilberberg et al., 2010
DOR 500 mg/8 hrs
Probability if DOR-S 0.815 0.764 0.857 Zilberberg et al., 2010
Probability if DOR-R/IMI-S 0.004 0.001 0.02 Zilberberg et al., 2010
Mortality rate if sensitive to initial empiric antibiotic 0.2 0.07 0.47 Zilberberg et al., 2010
Attributable mortality if resistant to initial empiric 
antibiotic
0.384 0.224 0.576 Zilberberg et al., 2010
Days before clinical response if sensitive to initial empiric 
antibiotic
3 2 4 Zilberberg et al., 2010
Days before clinical response if resistant to initial empiric 
antibiotic
6 4 8 Zilberberg et al., 2010
Days of clinical response 7 5.6 8.4 Zilberberg et al., 2010
Days in ICU if sensitive to initial response 10 7 14 Zilberberg et al., 2010
Days in ICU if resistant to initial response 13 10 17 Zilberberg et al., 2010
Total duration of initial treatment if resistant to initial 
empiric treatment
3 2 4 Zilberberg et al., 2010
Total duration of initial treatment if sensitive to initial 
empiric antibiotic (days)
10 7 14 Zilberberg et al., 2010
Total duration of alternative treatment if resistant to 
initial empiric antibiotic (days)
10 7 14 Zilberberg et al., 2010
Utilities
Utility before clinical response −0.402 −0.3216 −0.4824 Edwards et al., 2010
Treatment responder 0.712 0.5696 0.8544 Edwards et al., 2010
Patient recovered from infection 0.83 0.62 1 Zilberberg et al., 2010
Costs
Cost of one vial of IMI 500 70.71 EGP 56.57 EGP 84.85 EGP Healthcare hospitals
Daily cost of IMI 282.83 EGP 226.27 EGP 339.40 EGP Healthcare hospitals
Cost of one vial of DOR 500 80.00 EGP 64.00 EGP 96.00 EGP Healthcare hospitals
Daily cost of DOR 240.00 EGP 192.00 EGP 288.00 EGP Healthcare hospitals
Chest radiograph/24 hrs 16.00 EGP 12.80 EGP 19.20 EGP Healthcare hospitals
Arterial blood gas/12 hrs 50.00 EGP 40.00 EGP 60.00 EGP Healthcare hospitals
Electrolyte balance/24 hrs 10.00 EGP 8.00 EGP 12.00 EGP Healthcare hospitals
Liver function/24 hrs 20.00 EGP 16.00 EGP 24.00 EGP Healthcare hospitals
kidney function/24 hrs 16.00 EGP 12.80 EGP 19.20 EGP Healthcare hospitals
Cost of 1 day at ICU 90.00 EGP 72.00 EGP 108.00 EGP Healthcare hospitals
Cost of 1 day at ICU with ventilator 150.00 EGP 120.00 EGP 180.00 EGP Healthcare hospitals
Sensitivity test 15.00 EGP 12.00 EGP 18.00 EGP Healthcare hospitals
IMI-S: Imipenem-cilastatin sensitive, DOR-S: Doripenem sensitive, IMI-R: Imipenem-cilastatin resistant, DOR-R: Doripenem resistant, EGP: Egyptian pound, 
ICU: Intensive care unit
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of ≤4 µg/mL is susceptible, eight µg/mL is intermediate, and ≥16 µg/mL 
is resistant. For DOR, a MIC of ≤2 µg/mL is susceptible and ≥4 µg/mL is 
nonsusceptible [11].
According to these data, the rates of susceptibility utilized in the model 
were as follows: DOR-S 0.815 (95% CI: 0.764, 0.857), IMI-S 0.741 (95% 
CI: 0.685, 0.789), DOR-R/IMI-S 0.004 (95% CI: 0.001, 0.020), and IMI-R/
DOR-S 0.078 (95% CI: 0.052, 0.116). Although the point estimates for 
each parameter were used in the base case of the model, each estimate 
was varied along its corresponding 95% CI in the sensitivity analyses.
Attributable mortality rate and mortality rate reduction with 
appropriate treatment
The estimates for PA attributable deaths were reported by Brewer 
et al. [15]. In this single-center study of 38 consecutive PA-VAP patients, 
the PA-VAP-attributable mortality rate was 38.4% [15]. The mortality 
rate reduction conferred was estimated by timely institution of an 
appropriate therapy on the basis of a study by Edwards et al. [16], 
where the relative risk of death among patients with IMI-R versus 
IMI-S PA infections was 1.86 (95% CI: 1.38, 2.51) [16]. To calculate the 
mortality rate reduction attributable to appropriate empiric therapy of 
PA-VAP, this estimate was inverted.
Duration, dosage, and costs of treatment
According to the guidelines from the American Thoracic Society (ATS) 
and the Infectious Diseases Society of America (IDSA), a 10-day IMI 
treatment course was used in the base case for two reasons: (1) The 
guideline is vague on the recommended duration of treatment and (2) 
assuming a traditional 14-day course, reduction to 10 days represents 
an approximate adjustment for the fact that some patients die before 
completing their treatment [10]. The duration and dosage of DOR were 
based on the Phase III trial for this drug with a similar adjustment for 
early death [12]. This parameter was varied between 7 and 14 days for 
each strategy.
The daily IMI dose was 500 mg q6 hrs and that for DOR 500 mg q 8 hrs 
and was validated by an expert opinion. In the base case, a 3-day lag 
period between the onset of VAP and the availability of lower airway 
culture and sensitivity results was assumed, and was varied between 
2 and 4 days.
The patients treated with DOR testing positive for DOR-R/IMI-S PA were 
switched to IMI for an additional 10 days (range 7-14 days), and those 
treated with IMI testing positive for IMI-R/DOR-S PA were switched to 
DOR for an additional 10-day course (range 7-14 days). If a specimen 
tested positive for a PA sensitive to the initial empiric antibiotic, this 
antibiotic was continued for the full 10-day course (range 7-14 days).
Utilities and QALY
QALYs capture the benefits of an intervention in terms of survival 
and health-related quality of life (HRQoL). QALYs are calculated by 
multiplying the length of time affected by an intervention by the HRQoL 
or utility experienced during that time, where utility is measured on a 
scale from 0 (dead) to 1 (perfect health). A single year of perfect health 
would equal “1” while a single year at only half the level of perfect 
health would equal “0.5” [14]. Table 1 shows the daily proportion of 
a QALY attached to each of the health states within the model. The 
pragmatic decision was therefore made to use the utility score from the 
EuroQoL (EQ-5D) social tariff for “unconscious” (P. Kind, G. Hardman 
and S. Macran, unpublished).
RESULTS
Deterministic baseline results from the model of DOR compared to IMI 
in the treatment of VAP suggest that DOR is more effective and less 
expensive than IMI (Table 2). Direct medical costs were obtained from 
the healthcare hospitals in Egypt. Total costs for IMI and DOR were 
Egyptian pound (EGP) 4646.93 and EGP 4197.58, respectively. QALYs 
for IMI and DOR were 0.525222843 and 0.536769973, respectively. 
The incremental cost-effectiveness ratio for IMI versus DOR was 
L.E-38914.30/QALY (Table 3). This study showed that IMI is less 
effective and more costly compared to DOR in treating VAP patients.
As in all modeling exercises, several assumptions were made in this 
study leading to uncertainties in the results. In this analysis, it was 
explicitly accounted for these uncertainties by assigning CIs and 
plausible ranges based on published sources. To assess the influences 
of other model structures and assumptions on the cost-effectiveness 
estimates, one-way sensitivity analyses of various parameters were 
performed and showed that probability that patients are resistant to 
imipenem but sensitive to DOR (IMI-R/DOR-S), daily cost of IMI and 
DOR had the greatest impact on the results (Fig. 2).
DISCUSSION
This cost-effectiveness analysis shows that patients on MV who are 
suspected to have VAP, empiric treatment with DOR are not only 
cost-effective but cost saving when compared with treatment with 
IMI. Furthermore, as a hospital cost- and life-saving approach, DOR 
dominates the alternative of empiric IMI.
VAP remains a challenge in the ICU in general and even more so in surgical 
and trauma ICUs [17]. As it is caused by a resistant organism [18], and 
inappropriate empiric treatment of VAP results in a higher hospital 
mortality rate [19,20], there is a challenge in the choice of VAP 
treatment. To balance the benefit to the patient of broad initial coverage 
against the risk of further antimicrobial resistance development, the 
joint ATSIDSA guidelines highlight the need for broad initial coverage 
followed by de-escalation to the extent possible according to lower-
airway sampling [10]. At the same time, the value proposition for 
the advocated broad coverage needs to be made explicitly, given the 
higher costs of the newer broader-spectrum antibiotics than the older 
agents. This study builds on previous work investigating clinical and 
microbiologic comparisons between DOR and IMI by demonstrating 
cost savings with a DOR strategy over IMI as a treatment for suspected 
VAP, not only in the pharmacy acquisition costs but also in the overall 
hospital costs. By showing consistent hospital cost savings associated 
with DOR treatment, our results allow clinicians to focus on improving 
clinical outcomes for their patients with suspected VAP.
The main strengths of the study are the use of evidence from 
prospective, multicenter, parallel randomized study, and incorporating 
quality of life issues in clinical decisions. The study has a number of 
Fig. 1: Decision tree. Square node at left represents the decision 
to treat empirically with DOR or IMI. Circular chance nodes 
represent the probability of the various options for susceptibility 
of PA. The final circular event node represents the outcome: 
Death or survival. Rightmost vertical segments are terminal 
nodes. DOR: Doripenem, IMI: Imipenem-cilastatin, R: Resistant; 
S: Sensitive.
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limitations. First, the study was limited to PA patients as it is one of the 
leading pathogens in VAP. Second, because of the paucity of long-term 
data on VAP survivor published data on utilities in ICU so the utility 
score from the EuroQoL (EQ-5D) social tariff was used and it has been 
used in the previous studies [13,14].
In summary, the results from this study showed that IMI is less effective 
and more costly compared to DOR in the treatment of VAP. These 
findings will help to inform health-care decision makers regarding the 
allocation of health-care system resources to improve the health of the 
Egyptian population.
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